A POOLED ANALYSIS OF THE IMPACT OF AGE ON OUTCOMES IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE

被引：0

作者：

Palumbo, A. ^{[1
]}

Dimopoulos, M. A. ^{[2
]}

Richardson, P. G. ^{[3
]}

Siegel, D. S. ^{[4
]}

Cavo, M. ^{[5
]}

Corradini, P. ^{[6
]}

Weisel, K. C. ^{[7
]}

Delforge, M. ^{[8
]}

Chen, C. ^{[9
]}

Goldschmidt, H. ^{[10
,11
]}

Jagannath, S. ^{[12
]}

Lockhorst, H. M. ^{[13
]}

Moreau, P. ^{[14
]}

Plesner, T.

Sternas, L. ^{[16
]}

Peluso, T. ^{[15
,17
]}

Hong, K. ^{[16
]}

Herring, J. ^{[16
]}

Yu, X. ^{[16
]}

Zaki, M. H. ^{[16
]}

San Miguel, J. ^{[18
]}

机构：

[1] Univ Turino, Turin, Italy

[2] Univ Athens, Athens, Greece

[3] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA USA

[4] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[5] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

[6] Univ Milan, Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[7] Univ Hosp Tuebingen, Tubingen, Germany

[8] Univ Hosp Leuven, Leuven, Belgium

[9] Princess Margaret Hosp, Toronto, ON, Canada

[10] Univ Hosp Heidelberg, Heidelberg, Germany

[11] German Canc Res Ctr, Heidelberg, Germany

[12] Mt Sinai Hosp, New York, NY 10029 USA

[13] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[14] Univ Hosp Hotel Dieu, Nantes, France

[15] Univ Southern Denmark, Dept Hematol, Ctr Little Belt, Vejle Hosp, Vejle, Denmark

[16] Celgene Corp, Summit, NJ USA

[17] Celgene Int Sarl, Boudry, Switzerland

[18] Univ Navarra Clin, CIMA, IDISNA, Pamplona, Spain

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

E1295

引用

页码：535 / 536

页数：2

共 50 条

[41] Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma
Pierceall, William E.
Amatangelo, Michael D.
Bahlis, Nizar J.
Siegel, David S.
Rahman, Adeeb
Van Oekelen, Oliver
Neri, Paola
Young, Mary
Chung, Weiyuan
Serbina, Natalya
Parekh, Samir
Agarwal, Amit
Thakurta, Anjan
CLINICAL CANCER RESEARCH, 2020, 26 (22) : 5895 - 5902
[42] Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma
Chen, Christine
Kotb, Rami
Sebag, Michael
LeBlanc, Richard
Sutherland, Heather J.
White, Darrell
Venner, Christopher P.
Kouroukis, Tom
Bergstrom, Debra
McCurdy, Arleigh
Lalancette, Marc
Bensinger, William
Lentzsch, Suzanne
Del Col, Aldo
Kauffman, Michael
Shacham, Sharon
Jeha, Jacqueline
Picklesimer, Carla
Saint-Martin, Jean-Richard
Choe-Juliak, Cassandra
Bahlis, Nizar J.
BLOOD, 2016, 128 (22)
[43] Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
Dharshan Sivaraj
Michael M Green
Yubin Kang
Gwynn D Long
David A Rizzieri
Zhiguo Li
Anderson H Garrett
Jackie L McIntyre
Nelson J Chao
Cristina Gasparetto
Blood Cancer Journal, 8
[44] Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
Sivaraj, Dharshan
Green, Michael M.
Kang, Yubin
Long, Gwynn D.
Rizzieri, David A.
Li, Zhiguo
Garrett, Anderson H.
McIntyre, Jackie L.
Chao, Nelson J.
Gasparetto, Cristina
BLOOD CANCER JOURNAL, 2018, 8
[45] Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World 'Powerful' Study
Terpos, Evangelos
Repousis, Panagiotis
Lalayanni, Chrysavgi
Hatjiharissi, Evdoxia
Assimakopoulou, Theodora
Vassilopoulos, George
Pouli, Anastasia
Spanoudakis, Emmanouil
Michali, Evridiki
Pangalis, Gerassimos
Poziopoulos, Christos
Kyrtsonis, Marie-Christine
Pappa, Vassiliki
Symeonidis, Argiris
Georgopoulos, Christos
Zikos, Panagiotis
Papadaki, Helen A.
Dadakaridou, Magda
Karvounis-Marolachakis, Kiki
Patos, Petros
Katodritou, Eirini
BLOOD, 2020, 136
[46] Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT).
Vij, Ravi
Richardson, Paul Gerard Guy
Jagannath, Sundar
Siegel, David Samuel DiCapua
Baz, Rachid C.
Srinivasan, Shankar
Larkins, Gail
Zaki, Mohamed H.
Hussein, Mohamad A.
Anderson, Kenneth Carl
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[47] Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Richardson, Paul G.
Siegel, David S.
Vij, Ravi
Hofmeister, Craig C.
Baz, Rachid
Jagannath, Sundar
Chen, Christine
Lonial, Sagar
Jakubowiak, Andrzej
Bahlis, Nizar
Song, Kevin
Belch, Andrew
Raje, Noopur
Shustik, Chaim
Lentzsch, Suzanne
Lacy, Martha
Mikhael, Joseph
Matous, Jeffrey
Vesole, David
Chen, Min
Zaki, Mohamed H.
Jacques, Christian
Yu, Zhinuan
Anderson, Kenneth C.
BLOOD, 2014, 123 (12) : 1826 - 1832
[48] Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
Matsue, Kosei
Iwasaki, Hiromi
Chou, Takaaki
Tobinai, Kensei
Sunami, Kazutaka
Ogawa, Yoshiaki
Kurihara, Mari
Midorikawa, Shuichi
Zaki, Mohamed
Doerr, Thomas
Iida, Shinsuke
CANCER SCIENCE, 2015, 106 (11): : 1561 - 1567
[49] Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
Richardson, Paul G.
Facon, Thierry
Bensinger, William I.
Leleu, Xavier
Campana, Frank
Mace, Sandrine
Chiron, Marielle
van de Velde, Helgi
Mikhael, Joseph
BLOOD CANCER JOURNAL, 2021, 11 (03)
[50] POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE: A CHANCE FOR RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA. A REVIEW OF A CASE SERIES DIAGNOSED IN A SINGLE CENTER
Gil Perez, A.
de Miguel, D.
Subira, D.
Guillen, H.
Vazquez, A.
Diaz, M.
Golbano, N.
Morales, D.
Herrero, S.
Arbeteta, J.
Pinedo, B.
HAEMATOLOGICA, 2017, 102 : 804 - 805

← 1 2 3 4 5 →